BCL2L1 and cancer: By exploiting the fact that VHL is poorly expressed in platelets, DT-2216, a VHL-based heterobifunctional degrader, exhibits substantial BCL-XL degradation in cancer cells while having minimal effect on platelets, rescuing the compound from on-target and dose-limiting toxicity (93).